A key molecular mechanism that favors spreading of tumor cells to adjacent or distant regions of the body has been identified by researchers at the University of Kentucky Markey Cancer Center. This process is called metastasis and appears in breast cancer as well as in other types of this disease. As a result of this study, ways to new lines of research are opening, which aim at developing efficient treatments for metastatic breast cancer.
The team led by Peter Zhou, associate professor of molecular and cellular biochemistry at UK, concentrated on studying the process by which cancer cells stop holding tight to other cells and become capable to move and spread throughout the entire body. The results of the research were published in the EMBO Journal, the most representative publication of the European Molecular Biology Organization.
The motility of tumor cells is increased at the initial phase of metastasis and is similar to the epithelial-mesenchymal transition process (EMT) that is necessary for large-scale movement present in embryonic development, wound healing and tissue remodeling. It is known that during wound healing cells from the edge of the wound are subject to an EMT process and migrate to the middle of the wound in a sealing effect.
All EMT processes are characterized by loss of a cell-to-cell adhesion molecule called E-cadherin, which has the role of molecular glue. It attaches cells to each other. Breast cancer cells take control of this process and proceed to invasion and metastasis. When this molecular glue is destroyed, cancer cells start to migrate and then spread throughout the whole body.
Snail is a protein that acts in the cell’s nucleus, suppresses E-cadherin expression and induces EMT in the cell. As previous researches have shown, Snail is elevated in many forms of cancer, and particularly in breast cancer. Increased levels of Snail have been related to metastasis and tumor cell survival, as well as tumor recurrence. Scientists are not yet sure how Snail manages to trigger down-regulation of E-cadherin and induce metastasis in breast cancer.
Zhou and his team used a protein purification approach and found that Snail makes team with the LSD1 enzyme, inside the cell. LSD1 is already known to produce changes in the structure of DNA and inhibits the expression of many genes.
LSD1 is not chemically related to the hallucinogen LSD and stands for lysine-specific demethylase-1. It regulates the chromosome’s structure by removing a key methylation at histone H3, which is a core component warping the DNA into compact form. Thus, the closure of DNA is started and down gene expression, such as E-cadherin, is shut. According to Zhou’s team, the N-terminal portion of Snail molecules works as a molecular hook for recruiting LSD1 to the E-cadherin gene. This one, in turn, will shut down the expression of E-cadherin and will induce cancer cell invasion and metastasis.
This research has important clinical implications, as chemical agents or compounds that are able to break the interaction of Snail with LSD1 have great potential in metastatic breast cancer treatment. Scientists are exploring this idea and are committed to develop medication efficient in metastatic cancer treatment.
One of the most common forms of cancer in women, breast cancer determines an important rate of mortality. About 90 percent of death cases are caused by local invasion and distant metastasis. The average survival after the appearance of metastasis is about two years.
According to Peter Zhou, a good understanding of the mechanism of breast cancer metastasis will allow new therapeutic approaches and will make more efficient the combat against this terrible threat.

The investigation was released in the Cancer Research journal in its October edition. The investigators from the University of Texas Southwestern Medical Center discovered that if they gave the mice the BEZ235 medication prior to undergoing harmless radiation in order to counteract the cancerous cell development of DNA, the BEZ235 would counteract the activity of the PI3K protein which typically acts as a guardian of the tumor cells. This protein maintains the cancerous cells in life in the moment they are attacked and try to heal their broken DNA.

Besides the leading author, the team of investigators from the University of Texas comprised: doctor Erik Bey from the Harold C. Simmons Comprehensive Cancer Center, doctor Andrea Rabellino, doctor Katja Schuster, doctor Adi Gazdar, professor within the University of Texas Southwestern, Jake Hamon from the Center for Therapeutic Oncology Research, doctor David Boothman from the Simmons Comprehensive Cancer, researchers coming from the University of Camerino in Italy and Novartis Pharma in Switzerland. Their investigation was financed by funds coming from National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, United States Department of Energy and the American Italian Cancer Foundation.

The scientists observed this treatment opportunity in mice that underwent a transplant process with non-small cell lung cancer tumors from human beings.

During their observation process, the researchers discovered that the malignant tumors developing in the mice which were treated with just the BEZ235 has a decrease in size compared to those affecting mice which were not undergoing any type of treatments. Even though the malignant tumors did not grow in size, their life was not ended by administering the specific medication.

On the other hand, mice undergoing the BEZ235 treatment combined with low-dose radiation recorded many cases of total elimination of the malignant tumors.

The leading investigator was doctor Pier Paolo Scaglioni who is assistant professor of the internal medicine department within the University of Texas Southwestern. He stated that the findings of his research team regarding the combination of medication and low-dose radiation may prove to become an efficient treatment for counteracting non-small cell lung cancer in human beings.

The non-small cell lung cancer represents one of the main causes of cancer connected mortality on the whole Globe. The malignant cells usually favor transformations in the K-RAS which is a gene. People suffering from mutations of the K-RAS usually present an increased resistance to therapies comprising irradiation. This is the cause for which their life perspectives are unfavorable.

The K-RAS transformations trigger the networks or different pathways of various proteins that act as signals to activate. This signaling represents a key element in the development and growth of a malignant tumor. The PI3K represents just one of these proteins. At the moment of activation, it acts as a guardian which aids the cells in maintaining living functions even after their DNA was damaged and they try to heal it.

Some of the elements forming the signal networks comprising also the PI3K protein have been explored as various medication targets for counteracting malignant tumors. The clinical tested medication BEZ235 has been recently in experiments comprising clinical tests for counteracting the activity of the PI3K and the mTOR which represents a signaling protein, also.

As the leading investigator states there is no efficient treatment counteracting the non-small cell lung cancer which hosts transformations of the K-RAS.

Medical doctor Pier Paolo Scaglioni conducted the first tests in order to identify the efficacy of the BEZ235 drug and thus, they tested it alone. The team of investigators discovered that the BEZ235 stops the evolution and growth of the lung cancer malignant cells that were developed in the laboratory and the malignant lung cells that affect the mice.

As the leading author of this first research, doctor Georgia Konstantinidou states the findings of the investigators were shocking. However, they strived to discover a way for a faster malignant cell deterioration. They found put that by combining the tested medication with low-dose radiation, the success of their mission was assured. Doctor Georgia Konstantinidou is a post-doctoral scientist within the University of Texas Southwestern.

Doctor Pier Paolo Scaglioni`s research group observed that the malignant cells which were treated with the BEZ235 medication and low-dosed irradiation. The latter triggered slight breaks in the cellular genetic material but did not managed to affect them in a more effective way in order to destroy them. At the moment the DNA of the cell is broken, the malignant cells are aided by the PI3K signaling network in order to assure the cancer cell`s survival while it is healing its genetic material.

The team of investigators explained that the malignant cells needed the PI3K signaling pathway to assure they remain alive and without the protein`s response they were prone to die. This is why in the moment the scientists administered the BEZ235 medication it stopped the action of the PI3K protein and this means that the non-small cell lung cancer cells were starting to die.

As the leading author of the research explains the future stage of the study is that of administering the BEZ235 medication or similar drugs in clinical tests against the non-small cell lung suffering human beings. This could also be applied in clinical trials comprising people suffering from other types of malignant cells such as pancreatic, colon and thyroid cancers. There are the same with the non-small cell lung due to the fact that the PI3K signaling network also acts as an important agent in the malignant cells` evolution.

This environmental report is just a part of the process of taking care of the continuous and newly discovered problems regarding the pollutant agents of the environment and cancer. Moreover, the scope of the report is to shed more light on the principles, mission, values, objectives and various roles of the American Cancer Society on issues such as those mentioned before: pollution and malignant tumors prevention.

As the co-chair of the subcommittee and chairman of the Department of Preventive Medicine within the Keck School of Medicine of University of Southern California, medical doctor Jonathan Samet explains the problems regarding the environmental pollution agents affecting the air, water, food and thus, customer products represent issues on general public care and high unknowns. He also adds that their report aims to put the pollution agents of the environment in a greater relationship with preventing malignant tumors. The relationship focuses on reducing the smoking habit of the population, improving nutritional behavior, increasing the physical activities, maintaining a proper body weight and come up with vaccines that counteract the infections which may cause cancers.

The other co-chair of the subcommittee is also volunteer president of the American Cancer Society. Her name is Elizabeth “Terry” T.H. Fontham and she stated that the exposure levels of the population to chemical and pollution agents affecting the environment are much lower than the levels linked to the showed predisposition to developing malignant tumors in the jobs people have and other daily settings. However, the concern raised by the low exposure levels has to do with the fact that the number and types of pollution substances are increasing and may prove in the future to get out of the population`s control. In addition, the problems related to the fact that even low exposure levels bring some contribution to the cancer developing cases cause more reasons for distress considering the high number of persons who are daily exposed to the environmental pollutants.

The subcommittee`s report states that the scientific problems related to the exposure of people to the environmental pollutants represent complex issues just like increase in the number of landscape technologies which are utilized to analyze the chemical carcinogenicity. In spite of the capability of the nowadays tools used to identify and categorize proves for carcinogenicity, the subcommittee`s article states that there exist three main problems which constrain them from using them because there is a limited quantity of resources which are allotted to function those specific systems and from a scientific point of view, the environmental problems are complex and uncertain.

The report`s concerns about cancer vary and are related to malignant tumors prevention. There is a high need for new stratagems related to the tests done to evaluate the environment`s toxicity, comprising also the evaluation of carcinogenicity. These new strategies could be incorporated in such a manner as to assure a more efficient and effective screening process of a higher number of chemical agents which affect people daily. In addition, exposure to occupational and community settings should be regulated by some standards. The subcommittee draws attention on the need to support investigations aimed at identifying and decreasing the number of hazards provoked by carcinogens. Furthermore, the institutions that determine and implement standards for the environment must meet proper financing and appropriate technology in order to be near the scientific evolution and upgrade their set standards according to the new available data.

Even though some exposure cannot be avoided, this type of exposure must be somehow diminished and even stopped in the cases where it is possible to do so. In addition, the population must receive information about these matters in order to know their health status and risk of cancer or other diseases. Last, but not least, the media communication must make people aware of the situation of the exposure in an accurate manner and not to exaggerate or diminish the importance and level of environmental pollution factors.

The subcommittee’s report states that in order to create and implement this new initiative in order to assure the acquiring of more knowledge regarding the association between the levels of exposure to environmental pollution agents and the predisposition to various types of cancers, the American Cancer Society is going to further develop its long-run commitment to preventing malignant tumors. In addition, the American Cancer Society is also keen on studying these problems more thorough in order to discover new ways in which the initiative could bring more benefits in an effective and efficient manner.

The investigation of the Swedish researchers is released in the Arthritis & Rheumatism in the November edition which is a journal of the American College of Rheumatology by Wiley-Blackwell.

The tumor necrosis factor is a solution produced by the body`s immune system cells entitled cytokine. This substance has the role of regulator of the immune system and plays a great part in the inflammation process. Tumor necrosis factor inhibitors also known as blockers of the tumor necrosis factor represent a group of treatments that is utilized in counteracting swellings in chronic swellings such as the rheumatoid arthritis. The standard immunosuppressant medications and those comprised in the investigation are Enbrel®, Remicade® and HumiraTM. Due to the fact that these treatments are utilized in order to counteract the chronic swelling diseases, the long-run inhibition of the tumor necrosis factor determines debates on the enhanced predisposition to cancer or various infections.

The Swedish investigation represents one of the biggest and long lasting evaluations of the population in verifying the predisposition of developing malignant tumors linked to treatments that comprise immunosuppressive medications. The research incorporated information coming from various Swedish databases such as the Cancer Register, the Biologics Register and the Early RA Register.

The group of scientists observed and evaluated the data coming from 6,366 people who began anti- tumor necrosis factor treatment on a period ranging between January 1999 and July 2006. The information coming from patients who underwent tumor necrosis factor inhibiting therapies was later compared with some other groups of people who suffered from rheumatoid arthritis. These groups comprised 61,160 people who did not take any kind of drugs, 4,015 patients using the gold standard rheumatoid arthritis therapy entitled methotrexate and 4,015 individuals who took combinations of anti- rheumatoid arthritis medications that were known to modify the illness but different from the drugs inhibiting the tumor necrosis factor.

The outcome of the large investigation was that 240 first main cancers were diagnosed during the 25,693 human-being years of tracking in the people who underwent anti- tumor necrosis factor treatments who did not present any history of malignant tumors at the outbreak of the immunosuppressant drug therapy. In comparison with the bigger national rheumatoid arthritis group who did not get tumor necrosis factor inhibitor medications or who had developed malignant tumors in the past, the relative predisposition to develop cancer for patients who underwent anti- tumor necrosis factor treatments was 1.00 and did not change for the persons who took immunosuppressant medications for even six years.

As the leading investigator states their research pointed out the overall predisposition to cancer was the same for people who developed rheumatoid arthritis and were currently undergoing immunosuppressant treatments and those patients who did not take that type of medication in counteracting their illness. In addition, doctor Askling states that there are some uncertainties that remain under the sing of the doubt and recommends vigilance in these treatments in order to assure that nothing goes wrong.

The rheumatoid arthritis represents an autoimmune illness that has as symptoms chronic swelling of the joint, joint tissues and other organs. The RA is one of the most widely spread variant of swelling arthritis. Statistics released in 2004 by WHO (World Health Organization) stated that approximately 23.7 million individuals all over the Globe, from which 1.3 adults from the United States, suffered from rheumatoid arthritis. 75 percent of the 23.7 million cases represented the female gender.

An investigation set up on the “Asian paradox” was released in the World Journal of Gastroenterology in this year`s October edition. The investigation was led by medical doctor Murdani Abdullah who activates in the Division of Gastroenterology, Department of Internal Medicine within the University of Indonesia. The research started from an earlier concept developed by P. Correa. This is concerned with the fact that there are some changes in the mucosa triggered in a cascade manner which are triggered either by acute or chronic gastritis and develop into gastric malignant tumors.

The variations in the way Helicobacter pylori affects the gastric tract and produces gastritis might provide the explanations of the variety of gastric malignant tumors incidence between Japan and Indonesia, for example. Earlier research never took a closer eye at these transformations of the gastric mucosa which later developed into gastric cancer.

The recent investigation strives to observe the changes that occur in the gastric mucosa at the time when it is infected with Helicobacter pylori and develops gastric malignant tumors. The transformations of the gastric mucosa were observed in two Asian countries that present the “Asian paradox”: Japan and Indonesia.

Starting with the year 1998, 42 sick people from the Yamanashi Medical University Hospital located in Koufu and 125 patients from the Metropolitan Medical Centre Hospital located in Jakarta were enrolled for the period of one year (the duration of the research). Out of this investigation, it has been discovered that there is a complex variation in the activity and degree of the transformations that occurred in the gastric mucosa among the Japanese and Indonesia patients who underwent the study and tested positive for Helicobacter pylori. These discoveries may mean that the Indonesian and the Japanese population affected by the Helicobacter pylori infection present different responses to the infections.

The scientists who underwent this investigation think that agents that appear and affect people`s way of living and their genetic history are essential elements that trigger the “Asian paradox”. However, further researches need to be done in order to gather more information and knowledge about this matter and thus, to better understand the variations in patients suffering from infections with the Helicobacter pylori.

The MASCOT project was financed in part by the European Commission (IST-027652).

This device is the first of its kind because it comprises various significant preparation phases for samples and muxing based detection which was created and implemented in the lab-on chip. An interesting fact is that all the module complexes for investigating and mingling with the samples and the detection feature of the gadget are preparing to be even further minimized in order to be incorporated in just one lab-on-chip device. The researchers desire that this complex would become feasible in a medical manner in the Oslo during the studies of breast cancer treatments.

A great thing is that this circulating cancer diagnosis represents an important methodology for a personalized tracking of people who suffer from malignant tumors both in an early development stage and in an advanced one. This, in turn, would lead to an improvement in the physicians and surgeons` decision-making ability.

Taking into consideration breast cancer, 5 milliliters of blood comprise just two or three cells coming from tumors. In order to find out from the blood tests if someone has developed malignant tumors, the malignant cells circulating in the blood flow have to be isolated, caught and their genetics have to be observed.

The nowadays diagnostics done in the labs of the medical facilities are not time- and cost-effective and require a lot of work. This type of diagnosis might ask for a number of processing phases for the sample in various medical tools so the complete analysis of the sample is for sure to take more than 24 hours. On the other hand, the lab-on-chip technology could have many benefits for the entire medical world and the people who are ill. This innovative system is cost-effective, has easy usage and is very fast compared to the past methods. An interesting aspect of this technology is that it does not need medical laboratories and laborious hours. Instead, the tests comprised by the lab-on-chip can be undergone routinely either in the physician`s office or nearby the bed of the sick person. Thus, the lab-on-chip technology represent a time saving opportunity which does not require laborious work do be done in order to get the results to diagnosis tests. Moreover, it provides the minimum of body invasion in order to discover cancer cells and a customized treatment and screening.

The study`s collaborators created a modular platform in which every module performed a specific job and kept its independence. This endowment means that the technology can be utilized in numerous medical tests. The first module of the platform is the incubation one which has the role of mixing the blood under testing with specialized magnetic beads in order to link the tumor cells to one another. The second module has the role to isolate the malignant cells and count them thanks to a magnetic characteristic which can attract each cell and dielectrophoresis function. The third one is entitled the amplification module. It has the role to destroy the wall comprising malignant cells and by doing this the mRNA, the desired genetic material, is taken out from the sample and enhanced by using MLPA (multiplex ligation dependent probe amplification).

In the third module, certain procedures that measure the biochemical substances from the extracted substance enhance approximately twenty markers that are generated in the carcinoma cells of the breast. In the last module used for detection, the enhanced genetic substance is discovered by utilizing a series of electrochemical markers. These modules have been created and are feasible to use on the samples of blood.

The modules are prepared for advanced incorporation in just one lab-on-chip. By minimizing the size and linking the micofluidic and electronic functions of the technology, their accuracy and trustworthy character is enhanced in order to perform tests on sick people. The medical utilization of the lab-on-chip is going to be observed in order to see its similarities and differences compared to the existing methodologies used in the breast cancer treatments. This is going to be accomplished by a new investigation.

The COX-2 (Cyclooxgenase-2) represents an enzyme which synthesizes prostaglandin. An evolved expression of Cyclooxgenase-2 is found in a great variety of malignant tumors affecting human beings which also comprise the gastric cancer. Experiments done on animals revealed that a long-term treatment with medication that inhibits the gastric carcinogenesis related to Cyclooxgenase-2. However, using such inhibiting drugs on humans is still not done due to the fact that the medication can trigger harmful and even fatal cardiovascular side-effects. This is why it is of great importance to discover the best and harmless therapy comprising Cyclooxgenase-2 inhibiting medications that also inhibit the Helicobacter pylori linked to gastric carcinogenesis.

A recent study regarding this matter was released in the World Journal of Gastroenterology in the October edition. Professor Wu coming from the Department of Gastroenterology within the Kaohsiung Medical University Hospital was the leader of the investigation. He utilized the Mongolian gerbil model in order to observe the best point of Cyclooxgenase-2 inhibiting medication for inhibiting gastric carcinogenesis produced by Helicobacter pylori. This new research also takes a closer look at the chemotherapy use for preventing this condition and also at the adverse effects the Cyclooxgenase-2 inhibiting medication may produce to the human body.

Earlier investigations utilized chemotherapies on a long-run basis for preventing the gastric carcinogenesis. Nonetheless, the Cyclooxgenase-2 inhibiting drugs did not come in placebo format and affected the patients. This group of medications must not be utilized on a long-run basis in the chemoprevention of the gastric malignant tumors.

As the investigation pointed, Celecoxib is a drug which might trigger anti-oncogenic effects. It can also inhibit the angiogenesis and the spreading of malignant tumors in the whole body. Moreover, this medication proved to be efficient in obtaining these effects either if it was used on a short- or a long- term basis. Celecoxib acted as a guardian who connotes an early oncogenic stage and not an inflammatory one. In addition, the utilization on short-term of Celecoxib proved to bring harmless inflammations and also stopped the spreading of gastric malignant cells in the organism.

If we were to listen to what the investigation has to say, the short- and long-term use of Celecoxib for counteracting Helicobacter pylori` infection pathway in a medical case is the best thing to do. This finding has been never present in earlier researches. Thus, the new discovery is essential in diminishing the adverse effects produced by Cyclooxgenase-2 inhibiting drugs.

The team of investigators state that Cyclooxgenase-2 inhibiting medication might be utilized as a chemoprevention treatment for patients that are 40 years or older. This approach may prove to play an essential part in the life of patients who suffer from extended metaplastic gastritis with an enhanced predisposition of developing gastric malignant tumors. Moreover, the therapy is essential also for people who suffer from refractory Helicobacter pylori infections with an increased predisposition for gastric malignant tumors.

As a gastroenterological specialist stated the research outcome provides new insights into a customized treatment against gastric malignant tumors starting with the prevention phase and also it may bring advantages for medical therapy in the near future.
.

Earlier research which observed people that were not Jewish took a closer look at the association between the cancer occurrence rates and the psychological and physical stress which ranged from famine to mental ones. However, these past investigations did not managed to reach a conclusive outcome.

Lital Keinan-Boker who is a medical doctor in the School of Public Health, Faculty of Welfare and Health Sciences within the University of Haifa located in Israel, led a team of investigators in a research regarding the above mentioned association. The group of scientists observed a sample of approximately 300,000 Jews coming from Israel. A particularity of these Jews was the fact that they were born in Europe, but later, before and during the World War II they moved in Israel. One of the groups was exposed to the Holocaust, whereas the other one was not. The group which experienced the Holocaust was determined as such by taking into consideration their immigration to Israel dates, due to the fact that specific information about the exposure to the massacre experience was not available.

The thought exposure to the Holocaust was linked with an enhanced predisposition to cancer as a whole considered for all the born groups and both for males and females, in comparison with the cohort which was not exposed to this massacre. The most important links between cancer and Holocaust exposure were comprised by two types of malignant tumors: breast and colorectal. For example, the exposure at an earlier age appeared to be specifically linked to the enhanced predisposition to develop any particular case of cancer.

As the investigators of the research state that their findings come as direct shock information for all the Jewish people who survived the Second World War and as a consequence they are very important for the physicians of these patients all over the world and especially Israel due to the high immigration rates. The team of researchers sees its discoveries as a warranty for all the investigations that would arise on this subject in the future. They expect to see research done on case-control studies which would generate answers and more information and also state that their study presents past and actual agents of risk that may bias the study when utilizing individual information to investigate this matter.

A complementing editorial to this study is written by Stephen Hursting from the Department of Nutritional Sciences at the University of Texas and Michele Forman from the Department of Epidemiology, University of Texas, also activating in MD Anderson Cancer Center located in Houston. The two compare the outcomes of the above mentioned study and other researches from the past which presented the association between the reduction of eaten calories and the predisposition to cancer. Hursting and Forman state that the information acquired from the newer investigation comes as a supplement for the existing published data regarding the effects of a harmful reduction of daily and necessary calories that one eats and the cruel physical and psychological stress this practice is prone to produce in human beings.

As the editorialists explain, by putting alongside information coming from investigations done on animals and human beings it seems that even though by reducing the daily intake of calories may reduce also the risk of developing malignant tumors, these rather beneficial effects against cancer are diminished and even destroyed by the exposure to a very demanding and stressful experience. Furthermore, the two state that by studying the group of Jewish persons who were exposed to the cruel experience of the Holocaust during the first years of their life, a great deal of knowledge can be acquired about stress effects at a younger age, adaptation ability and predisposition to cancer after years passed from a very stressful experience.

This newly released screening framework is just the first step of the scientists from the M. D. Anderson Cancer Center to enhance the efficiency of forewarn and discover malignant tumors in their earliest development stage. Discovering cancer at this early development stage is of great importance because it can be more effectively treated through means such as rebuilding and developing even further its screening process. In addition, by doing this the risk of evolution and remission decreases and the worldwide medical world can acquire new diagnostic frameworks related to eight illness sites.

The suggestions regarding the screening process can be found on the Internet site of M. D. Anderson Cancer Center. These guidelines explain in a more comprehensible manner the best actions of admonishing malignant tumors that are undergone at this cancer center. This framework of practices is available for the general public to understand and it comprises the discovered risk classification and information regarding screening such as when it is most appropriate to start it and when it is all right to stop it.

As the American Cancer Society presents, over more than 40% of United States inhabitants are prone to suffer from malignant tumors during their life span. Furthermore, the types of cancer that can be avoided or discovered in early development stages due to screening sum up for minimum 50 percent of all these new malignant tumor occurrences.

Therese Bevers is the medical director of the M. D. Anderson’s Cancer Prevention Center. As the medical doctor state the screening process is not a generalized procedure. It depends on the individual. The center`s new suggestions aim to be more individualized, customized and more accurate. The new framework offers a more thorough recommendation compared to what was in the past made publicly available by other cancer institutions or by M. D. Anderson’s Cancer Prevention Center itself.

Until this recent investigation, suggestions for the screening process were dedicated in a larger manner to people who presented an average risk of suffering from cancer. These past recommendations based themselves on features such as age and family and genetic history and risk. Nonetheless, this average predisposition had not been clearly formulated and suggestions for people who presented a high risk of developing malignant tumors were not presented.

With the appearance of this new research there come new recommendations regarding cancer screening comprised in a new framework. These suggestions target individuals who present an increased predisposition of suffering from cancer. A feature which differentiates this new set of guidelines is, for example, the fact that the new framework comprises five various sets of suggestions for cancer screening for people who show a high predisposition of developing cancer, four categories of suggestions regarding cervical malignant tumors from the point of view of age-related risk. Regarding the colorectal malignant tumors, three new categories are presented in this new set of screening guidelines targeting people who present a high predisposition of developing this type of cancer and other three categories targeting individuals who show an increased predisposition for the colorectal cancer.

This new developed framework is constructed based on the early accepted screening activities, but it is more accurate and specific in offering suggestions, as follows:

Guidelines for Breast Cancer

Beginning with the age of 20 years, women who present all the predisposition levels of developing breast malignant tumors should take a closer look at the anatomy of their breasts and palpate them in order to discover whether sudden changes have appeared. If they notice a transformation of their breasts, the females should immediately go to their doctor and present their situation. Women who are 40 years or older and present an average predisposition to breast cancer should get breast tests and mammograms on a yearly basis.

For those females who present a high risk of developing malignant breast tumors, the frequency and variety of the breast tests depend on agents that represent their enhanced predisposition such as: their family history and thus, genetic risk, the past radiation therapy for counteracting breast tumors, a Gail Model score above 1.7% and the lobar carcinoma diagnosis established on the ground. Therapies recommended for this category of patients comprise breast tests done a specialized medical facility, MRI fro breasts and mammograms.

Guidelines for Cervical Cancer

Females who present an average predisposition for developing cervical cancer, the new guidelines suggest that those who are aged less than 21 years get a liquid based cytology or a Papanicolau tests in maximum three years after their first sexual intercourse. The woman should get Papanicolau tests done on a yearly basis until she scored three consecutive negative results. After this process, the scientists from M. D. Anderson’s Cancer Prevention Center suggest that the girl would undergo a once every two years screening if she does not present an enhanced predisposition of developing cervical cancer. The agents of risk comprise: immune system that does not operate accurately, the presence in the woman`s system of HIV (Human Immunodeficiency Virus), family history such as exposure before her birth to DES (diethylstilbestrol), the history of one`s cervical malignant tumors and advanced cervical dysplasia and continuously getting HPV (Human Papilloma Virus) positive results.

Starting with 30 years of age, the scientists recommend also testing for the Human
Papilloma Virus instead of the Papanicolau test and in the situation that both come up negative, a female could undergo tests once every three years unless she presents an enhanced predisposition to cervical cancer based in the mentioned agents or unless the recommended Human Papilloma Virus testing was not undergone.

Guidelines for Colorectal Cancer

The new investigation provided by the scientists from M. D. Anderson’s Cancer Prevention Center suggests that a colonoscopy should be done once every ten years and a virtual colonoscopy once every five years. The latter can be substituted by a FOBT (Fecal Occult Blood Test) done on a yearly basis in the case of both men and women who are 50 years or older and who present an average predisposition of developing colorectal cancer.

Taking into consideration both men and women who present an enhanced predisposition or a high risk of developing colorectal malignant tumors, the frequency and variety of medical tests depend on a series of agents such as: genetic history and diagnosis of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis, ulcerative colitis, Crohn’s disease or any other inflammatory bowel disease, family and personal history of colorectal cancers or adenomatous polyps. Therapies recommended for this risk group comprise colonoscopies and flexible sigmoidoscopy.

Ernest Hawk is the vice-president of the Cancer Prevention and Population Sciences. As this medical doctor states due to the fact that the investigation was done both in labs and clinics within the M. D. Anderson’s Cancer Prevention Center and all over the Globe, the knowledge and comprehension regarding the means by which malignant tumors appear and develop are continuously increasing.

This constant increase in the acquired information is going to lead in a more transparent understanding from the patients` behalf of just how their physicians settle on a specific decision related to the screening exams and levels of risk. Furthermore, the cancer suffering people would be also able to comprehend better the way their illness functions and evolves and is prone to make them assess their own predisposition to developing cancer.

As doctor Bevers explains in the case of colorectal malignant tumors screening, patients have to present a proactive attitude about obtaining outcomes from their testing processes. Take for example the case in which polyps are uncovered during a colonoscopy. It is very important for the person in case to understand what type, size and number the polyp has since this discovery has a great deal to do with the predisposition category the patient belongs to.

The categories of cancer predisposition and linked frameworks were created by many departments coming from M. D. Anderson’s Cancer Prevention Center comprising: medical and surgical oncology, imaging, cancer prevention and so on and so forth. The framework related to the screening based on the predisposition of developing prostate, skin, liver, ovarian and endometrial malignant tumors is now underway. Furthermore, a new Internet tool for assessing one`s predisposition to cancer which in linked to the future guidelines is going to be released on the M. D. Anderson’s Cancer Prevention Center Internet site in the beginning of the year 2010.

Authors that developed this investigation are as follows: Eric Campbell from the Institute for Health Policy, Sharon Bober, Christopher Recklitis, and Lisa Diller from the Perini Family Survivors’ Center within the Dana-Farber Cancer Institute and Jean Kutner from the University Of Colorado Denver School Of Medicine. Their research is released in the Journal of General Internal Medicine. The survey was financed by grants offered by the Swim Across American Foundation and the American Cancer Society.

This investigation is going to be released in this month`s supplement of the Journal of General Internal Medicine. However, the research is available in the Internet version of the journal. In this investigation, the scientists state that more than 50 percents of the internists that gave full disclosure to an inquiry reported that they seldom or even never communicated with their cancer survivor patients about the latter sexual dysfunctions.

Leading the research in this matter was Doctor Elyse Park from the Institute for Health Policy within the Massachusetts General Hospital. As the author states the sexual problems that face cancer survivors represent an essential feature in the life quality matter. If discussions regarding this matter do not take place in the office of each patient`s prime care doctor, it is for sure that they would not take place anywhere else.

The quality-of-life maters are growing in importance due to the fact that nowadays there are many people who suffer from cancer and manage to survive it. The sexual problems are very common in the cases of prostate and breast malignant tumor survivors, but they also appear in important figures regarding patients who survived other forms of malignant tumors. These sexual dysfunctions could be the outcome of the treatment against cancer or from the disease itself. In addition, many of the sick people could also present signs of depression, concerns related to their body appearance which can lead to a lack of sexual desire, anxiety, sexual functionality and privacy.

Even though there are numerous efficient therapies against these sexual dysfunctions, the investigators explain that these types of treatments can commence only after the cancer surviving patient has been identified. As a key note for the study, the primary care doctor of each and every cancer surviving person is the highest authority in identifying the people faced with sexual problems and providing them with assistance in this matter.

The research undergone by the team of investigators from the Massachusetts General Hospital is part of a bigger survey regarding the care of primary physicians for their patients who managed to survive malignant tumors. This scientific survey was sent and completed by more than 200 internists who collaborate with the University of Colorado. Some of the questions comprised by this inquiry were related to how often the internists started talking with their adult cancer surviving patients about sexual problems and the manner in which they addressed such issues.

The outcomes of the survey were that just 46% of the questioned internists stated that they pondered the idea of discussing sexual dysfunction issues with their patients and 62% of them said that they either never of seldom would initiate a discussion about sexual problems with their patients.

The elements linked to a physician`s ability and desire to initiate discussions regarding sexual dysfunctions were the direct interaction with the patient done frequently and the ability of showing a greater emotional intelligence in better caring for patients who survived malignant tumors on a general basis. An additional factor related to a physician’s willingness to initiate a discussion on the sexual problem subject is the ability to perceive the patients` fears and thoughts about their health and dysfunctions. The lack of the internists` time in addressing such dialogues was not considered a barrier in providing care.

As the leading author of the research states even if the discussions on the topic of sexual dysfunctions did not seem to be considered as a standard in providing medical care to people who survived cancer, if the internists felt the need or noticed that some worrying issues troubled their patients, then they would be more prone to initiate communication on this subject.

In addition, the senior researcher explained that people who survived malignant tumors usually presented in an open manner their anxieties and depression states linked to their illness or the treatment counteracting it. However, none of the sexual dysfunctions were mentioned during such conversations. Being also a psychologist in clinical care and assistant professor in the Psychiatry department within Harvard Medical School, doctor Parks states that in numerous if not all cases, sexual dysfunctions affect cancer surviving patients. These issues represent great problems which affect the quality of the patients` lives, but they are seldom discussed during the visit to the primary care physician.

The investigators suggest the need for more training in order to assure a better preparation on the internists and primary doctors` behalf in discussing with their patients about the sexual dysfunctions and matters.